Please assess the completion status of the following clinical trial:

Trial Title: Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 years or more,~* Performance status (WHO) ≤ 2~* Ability to participate in the IPCAPA program and medical certification of no contraindications to exercise~* Availability and willingness to participate in the IPCAPA study for the duration of the protocol~* Affiliated to a social security system~* Signed informed consent.~Exclusion Criteria:~* Pregnant or breastfeeding woman.~* Woman with childbirth ability without effective contraception.~* Patient in emergency situations, adult subject to a measure of legal protection (major trusteeship, guardianship or ward of court), or unable to consent.~* Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.~* Inability to practice physical activity.~* Planned surgery within 24 weeks of inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate adaptated physical activity (Group A) (Type: OTHER): Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4).
- Without immediate adaptated physical activity (Group B) (Type: OTHER): Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4).

Based on this trial design, predict the completion outcome and termination type (if applicable).